Prometheus Biosciences

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Precision IBD is a Biotechnology company and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases.

Affirm

Dutch Bros

Kanzhun Ltd

Doximity

Digital World Acquisition Corp

Global-e Online Ltd

TaskUS

Verve Therapeutics

ZIM Integrated Shipping Services

Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.

These were the 10 best performing IPOs of 2021 amid a record year for stock market debuts

Biogen

Longeveron

Check out these biotech stocks turning heads in the stock market now.

3 Biotech Stocks To Watch On Pfizer's Latest Omicron Update

Prometheus displays positive phase 1 safety data with PRA023. Drug also shows target engagement with mode of action in healthy volunteers. Based on the phase 1 data, biotech has added a 3rd indication for PRA023, which is Systemic Sclerosis-Associated Lung disease. Phase 1 study to start Q1 of 2022.

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Prometheus Biosciences Inc (NASDAQ: RXDX) has reported topline results from its Phase 1 trial of PRA023 in healthy volunteers. PRA023 was well-tolerated, with no safety signal identified during the study.

Prometheus Biosciences Posts Phase 1 Data On Lead Therapeutic Candidate

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 -

Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress

Lantronix

One way to find potential winning stocks is to search for companies that recently landed new analyst coverage.

How to Use New Analyst Coverage to Find Strong Stocks to Buy

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that management will be conducting presentations and fireside chats at the following investor conferences in November and December.

Prometheus Biosciences to Present at Upcoming Investor Conferences

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET.

Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

The shares of Prometheus Biosciences Inc (NASDAQ: RXDX) have received a $35 price target by Oppenheimer. These are the details.

RXDX Stock: $35 Price Target By Oppenheimer

Prometheus has built the leading platform and data set for IBD drug development that has enabled partnerships, a diverse pipeline, and non-dilutive capital. IBD is a market opportunity representing millions of patients, which has had little innovation over the last 2 decades.

Prometheus Biosciences: Precision Medicine For IBD

- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) -

Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021.

In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away

- First Anti-TL1A trial in Crohn's Disease -

Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn's Disease

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600-

Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, and Laurens Kruidenier, CSO, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30am ET.

Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

Genetron Holdings

World Acceptance

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

3 Small Cap Stocks That Are Short Squeeze Candidates

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

ThermoGenesis Holdings, Inc

Vyant Bio

3 Short Squeeze Candidates In The Health Care Sector

CytoDyn Inc.

Auris Medical Hld

Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.

Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today

Advanced Micro Devices

Curis

Alphabet

Microsoft

Visa

Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Time Picks, a Premium feature.

Steven Cohen Dives Deeper Into Health Care

Coupang

Keurig Dr Pepper Inc

Biohaven Pharmaceutical Hld

GoHealth, Inc.

Innoviva

JOANN

Merchants Bancorp

PennyMac Financial Services

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More

SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the closing of its initial public offering of 11,500,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares, at a public offering price of $19.00 per share. All of the shares were offered by Prometheus.

Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

News for Prometheus Biosciences Stock (RXDX)